|1.||Nakshatri, Harikrishna: 9 articles (05/2011 - 08/2004)|
|2.||Sweeney, Christopher J: 8 articles (05/2011 - 08/2004)|
|3.||Jordan, Craig T: 7 articles (11/2015 - 06/2005)|
|4.||Crooks, Peter A: 7 articles (11/2015 - 06/2007)|
|5.||Kim, In Hee: 6 articles (07/2015 - 07/2012)|
|6.||Kim, Se-Lim: 6 articles (07/2015 - 10/2012)|
|7.||Kim, Seong Hun: 6 articles (07/2015 - 07/2012)|
|8.||Lee, Seung Ok: 5 articles (07/2015 - 07/2012)|
|9.||Lee, Soo Teik: 5 articles (07/2015 - 07/2012)|
|10.||D'Anneo, Antonella: 5 articles (06/2015 - 06/2011)|
12/15/2015 - "Given the current deployment of parthenolide as an anti-cancer drug in clinical trials and the potential usage of this lactone as a cardioprotectant, it is important to examine in details the perturbing effects of parthenolide on Ca(2+) homeostasis in endothelial cells and neighboring vascular smooth muscle cells, activities of which exert profound effects on hemodynamics. "
05/01/2013 - "Candidate drugs identified by our approach may provide the groundwork for a combination therapy approach for cervical cancer; however, further studies are still needed to make sure that the use of parthenolide or other anti-cancer agents is effective without inhibiting important host defense mechanisms in cervical cancer."
02/01/2013 - "The aim of the present study was to investigate the effects of parthenolide on heterogeneous cancer cell populations from anchorage-independent melanospheres. "
10/01/2012 - "It includes parthenolide, a highly cytotoxic SL that is being tested in clinical trials as an anti-cancer agent. "
06/01/2012 - "Parthenolide has been tested for anti-tumor activities, such as anti-proliferation and pro-apoptosis in recent studies. "
|2.||Melanoma (Melanoma, Malignant)
02/01/2010 - "The aim of the study was to examine anticancer effects of parthenolide in melanoma cells in vitro. "
02/01/2013 - "The potential clinical significance of our findings is based on the ability of parthenolide to affect both bulk and melanoma stem-like cells with clonogenic capacity and high expression of the ABCB5 transporter. "
02/01/2013 - "Most importantly, melanoma cells that survived parthenolide treatment lost their self-renewing capacity. "
02/01/2013 - "In melanoma cells that survived treatment with parthenolide, a different immunophenotype than that in untreated control was found. "
02/01/2013 - "Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres."
|3.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
07/01/2009 - "This study elucidated the cellular responses induced by parthenolide that decrease the threshold of mitochondria-dependent apoptosis in the treatment of non-small cell lung cancer cells."
07/01/2009 - "Nuclear factor-kappaB inhibition by parthenolide potentiates the efficacy of Taxol in non-small cell lung cancer in vitro and in vivo."
11/01/2010 - "Paclitaxel efficacy is increased by parthenolide via nuclear factor-kappaB pathways in in vitro and in vivo human non-small cell lung cancer models."
11/01/2009 - "These data strengthen the rationale for using parthenolide to decrease the apoptotic threshold via caspase-dependent processes for treatment of non-small cell lung cancer with paclitaxel chemoresistance."
05/12/2012 - "Mixed micelles of PEG(2000)-DSPE and vitamin-E TPGS for concurrent delivery of paclitaxel and parthenolide: enhanced chemosenstization and antitumor efficacy against non-small cell lung cancer (NSCLC) cell lines."
01/01/2015 - "These data will be helpful for future investigations into the effects of parthenolide on inflammation. "
02/01/2011 - "Parthenolide, an inhibitor of the NFκB pathway, counteracted PI-induced increased inflammation and decreased glyceroneogenesis. "
05/01/2009 - "Parthenolide pretreatment inhibited bladder inflammation as well as bladder overactivity and it was also associated with nuclear factor-kappaB activation in the bladder. "
12/01/2002 - "This finding raises the potential to develop parthenolide to treat IL-4-mediated allergic-like inflammation."
08/01/2014 - "Parthenolide, a natural product derived from Feverfew, prevents septic shock and inflammation. "
|5.||Migraine Disorders (Migraine)
11/01/2003 - "This study examined the intestinal epithelial membrane transport of the sesquiterpene lactone parthenolide, a bioactive compound present in the migraine prophylactic herb feverfew. "
03/13/2015 - "Feverfew (Tanacetum parthenium) leaves have been traditionally used in the treatment of migraine with parthenolide being the main bioactive compound. "
01/01/2010 - "Besides its anti-inflammatory and anti-migraine properties, parthenolide also shows anticancer activities in a variety of cell lines. "
10/01/2000 - "Parthenolide, a biologically active sesquiterpene lactone found in feverfew [Tanacetum parthenium (L.) Schultz Bip., Asteraceae], has been indirectly linked to the anti-migraine action of feverfew preparations. "
03/01/1999 - "Parthenolide, a clinically useful agent and migraine prophylaxis principle from the medicinal plant, feverfew (Tanacetum parthenium), was tested on two tumor cell lines for its ability to inhibit cell growth. "
|1.||NF-kappa B (NF-kB)
|3.||Transcription Factors (Transcription Factor)
|4.||RNA (Ribonucleic Acid)
|5.||Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
|6.||STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)
|8.||Tumor Suppressor Proteins (Proteins, Tumor Suppressor)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)